Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SRPT stock price vs PEB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PEB's multiple
Needs PEB P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · PEB FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
PEBBLEBROOK HOTEL TRUST · implied price per share
Bear
-$8.17
Base
-$9.62
Bull
-$11.06
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
0.86x
Net debt / EBITDA
Leverage against operating earnings
0.01x
11.93x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$184.19M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
HOST HOTELS & RESORTS, INC.
SRPT vs HST
Apple Hospitality REIT, Inc.
SRPT vs APLE
Sunstone Hotel Investors, Inc.
SRPT vs SHO
Braemar Hotels & Resorts Inc.
SRPT vs BHR
$934.46M
$2.12B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can convert its 15.6% revenue growth into sustained margin improvement and better quality metrics, then the stock could be attractive at 0.9x P/S because the valuation discount versus PEB is meaningful; if not, the weak F-Score and negative Z-Score argue for caution.
On the provided P/S basis, SRPT trades at 0.9x versus PEB at 1.4x, which implies a meaningful valuation discount and supports the stated implied price of $30.23, or 56.6% above the current price. However, PEB-implied range is very wide and the historical band of $17.37 to $21.23 places SRPT near the upper end of its own recent trading range, suggesting the discount is not necessarily extreme in context.
Supporting Metrics
